Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease-Reference-Cited by-同舟云学术

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease

Published:2019-07-01 Issue:7 Volume:4 Page:691
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Fonarow Gregg C.¹²,van Hout Ben³,Villa Guillermo⁴,Arellano Jorge⁵,Lindgren Peter⁶⁷

Affiliation:

1. Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles Medical Center, Los Angeles

2. Section Editor, JAMA Cardiology

3. ScHARR School for Health and Related Research, University of Sheffield, Sheffield, England

4. Amgen (Europe) GmbH, Zug, Switzerland

5. Amgen Inc, Thousand Oaks, California

6. The Swedish Institute for Health Economics, Lund, Sweden

7. Department of Learning, Informatics, Management and Ethics, Karolinska Institute, Stockholm, Sweden

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

http:///jamacardiology/article-pdf/4/7/691/17729209/jamacardiology_fonarow_2019_br_190011.pdf

Reference8 articles.

1. Evolocumab and clinical outcomes in patients with cardiovascular disease.;Sabatine;N Engl J Med,2017

2. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease.;Fonarow;JAMA Cardiol,2017

3. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy-breakthrough in low-density lipoprotein cholesterol lowering, breakdown in value.;Mark;JAMA Cardiol,2017

4. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Grundy;J Am Coll Cardiol,2018

5. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial.;Arrieta;JAMA Cardiol,2017

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data;High Blood Pressure & Cardiovascular Prevention;2024-02-03

2. Improving Stroke Risk Factor Management Focusing on Health Disparities and Knowledge Gaps;Stroke;2024-01

3. Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study;2023-12-07

4. A review of cost-effectiveness analysis: From theory to clinical practice;Medicine;2023-10-20

5. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease;Current Pharmaceutical Design;2023-09-06